How low is the α/β ratio for prostate cancer?

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 4, 2003, Pages 1116-1121

  Kal, Henk B ^a   Van Gellekom, Marion P R ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Alpha beta; Brachytherapy; Edema; Prostate cancer; Repopulation

Indexed keywords

DOSIMETRY; IMPLANTS (SURGICAL); TUMORS;

PROSTATE CANCER;

RADIOTHERAPY;

IODINE 125; PALLADIUM 103;

ALPHA RADIATION; ARTICLE; BEAM THERAPY; BETA RADIATION; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DATA ANALYSIS; DOSE CALCULATION; EDEMA; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; RADIOACTIVITY; RADIUM THERAPY; TREATMENT OUTCOME;

EID: 0142186650     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)01455-X     Document Type: Article

References (21)

1. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 43:1999;1095-1101.
2. Fowler J., Chappell R., Ritter M. Is α/β for prostate tumors really low? Int J Radiat Oncol Biol Phys. 50:2001;1021-1031.
3. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 52:2002;6-13.
4. Wang J.Z., Guerrero M., Li X.A. How low is the α/β ratio for prostate cancer? Int J Radiat Oncol Biol Phys. 55:2003;194-203.
5. Brenner D.J. Toward optimal external-beam fractionation for prostate cancer. Int J Radiat Oncol Biol Phys. 48:2000;315-316.
6. Logue J.P., Cowan R.A., Hendry J.H. Hypofractionation for prostate cancer. Int J Radiat Oncol Biol Phys. 49:2001;1522-1523.
7. Dale RG, Jones B. Is the alpha/beta for prostate tumors really low? In regard to Fowler, et al., IJROBP 2001;50:1021-1031. Int J Radiat Oncol Biol Phys 2002;52:1427-1428.
8. Lee WR. In regard to Brenner, et al. IJROBP 2002;52:6-13. Int J Radiat Oncol Biol Phys 2002;53:1392.
9. Levegrun S., Jackson A., Zelefsky M.J., et al. Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer Pitfalls in deducing radiobiologic parameters for tumors from clinical data. Int J Radiat Oncol Biol Phys. 51:2001;1064-1080.
10. Barendsen G.W. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 8:1982;1981-1997.
11. Dale R.G. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 58:1985;515-528.
12. Van Gellekom M.P.R., Moerland M.A., Kal H.B., et al. Biologically effective dose for permanent prostate brachytherapy taking into account post-implant edema. Int J Radiat Oncol Biol Phys. 53:2002;422-433.
13. rd edition, 2002. Arnold, London. ISBN 0340 80783 0.
14. Haustermans K., Fowler J.F. A comment on proliferation rates in human prostate cancer. (letter) Int J Radiat Oncol Biol Phys. 48:2000;297.
15. Steel G.G. Cellular sensitivity to low dose-rate irradiation focuses the problem of tumour radioresistance. Radiother Oncol. 20:1991;71-83.
16. Waterman F.M., Yue N., Corn B.W., et al. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry An analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys. 41:1998;1069-1077.
17. King C.R., DiPetrillo T.A., Wazer D.E. Optimal radiotherapy for prostate cancer Predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models. Int J Radiat Oncol Biol Phys. 46:2000;165-172.
18. Armpilia C.I., Dale R.G., Coles I.P., Jones B., Antipas V. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Radiat Oncol Biol Phys. 55:2003;378-385.
19. Withers H.R., Taylor J.M., Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 27:1988;131-146.
20. Chappell R., Fowler J.F., Ritter M.A. In response to drs Dale and Jones. Int J Radiat Oncol Biol Phys. 52:2002;1428.
21. Lindsay P.E., Moiseenko V.V., Van Dyk J., Battista J.J. The influence of brachytherapy dose heterogeneity on estimates of α/β for prostate cancer. Phys Med Biol. 48:2003;507-522.